AKRX News 38.43 08/26/2014 04:28:59 Akorn Inc (AKRX)

New Post Public Reply Private Reply Replies (0) Message Board

Aug 26, 2014 at 5:28 AM

Akorn Inc (AKRX) 38.43 $AKRX

Stocks Rise As Biotechs Lead; Amazon To Buy Twitch
at Investor's Business Daily - Mon Aug 25, 3:58PM CDT
Stocks were moderately higher Monday with biotech stocks leading the way. The Nasdaq and the Dow Jones industrial average rose 0.4% and the S&P 500 gained 0.5%, closing above the 2000 level for the first time. After the close, Amazon (AMZN) announced...

Stocks Higher With Biotechs Leading The Way
at Investor's Business Daily - Mon Aug 25, 3:34PM CDT
The stock market was moderately higher Monday, with the S&P 500 topping 2000 intraday for the first time. Biotechs led the way on the strength of a major takeover. The Nasdaq and Dow industrials rose 0.4% each; the S&P 500 gained 0.5%. Nasdaq volume...

Main Indexes Slip From Highs; Biotechs Show Strength
at Investor's Business Daily - Mon Aug 25, 12:27PM CDT
Stocks backed off session highs Monday, but were still nicely higher in early afternoon trading. The S&P 500 and Dow Jones industrial average each rose 0.4%. while the Nasdaq added 0.2%. Gains for the S&P 500 and Nasdaq hit 0.7% intraday. Turnover...

Akorn Up 53.1% Since SmarTrend Uptrend Call (AKRX)
Comtex SmarTrend(R) - Fri Aug 22, 10:59AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 4 months, Akorn has returned 53.08% as of today's recent price of $37.58.

Actavis Up on Positive Phase III Ceftazidime-Avibactam Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:30PM CDT
Actavis plc's (ACT) shares were up 2.3% with the company announcing positive top-line results from the phase III RECLAIM-1 and -2 studies on ceftazidime-avibactam.

Akorn Larger Than S&P 500 Component Rowan Companies
TheOnlineInvestor.com - Wed Aug 20, 3:41PM CDT
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Akorn Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Rowan Companies plc , according to The Online...

Should You Get Rid of Corium International (CORI) Now? - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Wed Aug 20, 7:55AM CDT
Corium International stock could bring additional losses for your portfolio

Mallinckrodt Acquires Questcor, to Join S&P 500 As Well - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:30PM CDT
Mallinckrodt announced the completion of its acquisition of Questcor Pharmaceuticals, Inc. in a deal valued at approximately $5.8 billion.

Supernus's SPN-810 Gets Fast Track Status for ADHD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:30PM CDT
Supernus Pharmaceuticals, Inc.'s (SUPN) attention deficit hyperactivity disorder (ADHD) candidate, SPN-810 has received Fast track status in the U.S.

Stock Futures Steer Higher; Dollar General, Akorn Rising
at Investor's Business Daily - Mon Aug 18, 8:04AM CDT
Stock futures were up and holding near early highs ahead of Monday's open, boosted by rallying European markets. Dow futures traded ahead 87.1 points. Nasdaq 100 futures were 20.3 points above fair market value. S&P 500 futures rose 10.7 points, and...

Akorn Has Returned 47.5% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Fri Aug 15, 9:40AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 4 months, Akorn has returned 47.54% as of today's recent price of $36.22.

Perrigo Beats on Q4 Earnings and Sales, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 12:29PM CDT
Perrigo (PRGO) reported higher than expected earnings and revenues in the fourth quarter.

Akorn,Dean Foods, IMAX, Walt DisneyandLions Gate Entertainmenthighlighted as Zacks Bull and Bear of the Day
PR Newswire - Thu Aug 14, 8:30AM CDT
Zacks Equity Research highlights Akorn Inc (Nasdaq:AKRX-Free Report) as the Bull of the Day and Dean Foods Corp (NYSE

F-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onIMAX Corp. (NYSE:IMAX-Free Report), Walt Disney Company (NYSE

IS-Free Report) and Lions Gate Entertainment Corp. (NYSE:LGF-Free Report).

Cerulean Pharma (CERU) Worth Watching: Stock Soars 30.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:25AM CDT
Cerulean Pharma (CERU) was a big mover last session, with shares surging nearly 31% on the day.

Mallinckrodt Beats on Q3 Earnings and Revenues, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:23PM CDT
Shares of Mallinckrodt plc (MNK) gained 0.46% following the company's third quarter fiscal 2014 (ended Jun 27, 2014) earnings report last week.

SmarTrend Watching for Potential Pullback in Shares of Akorn After 1.63% Gain
Comtex SmarTrend(R) - Tue Aug 12, 4:48PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $34.57 to a high of $35.62. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $35.39 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Akorn Completes Acquisition of VersaPharm
GlobeNewswire - Tue Aug 12, 8:02AM CDT
Akorn, Inc. (Nasdaq:AKRX), a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of VPI Holdings Corp., the parent company of VersaPharm Incorporated, for $440 million.

Relypsa (RLYP) Worth Watching: Stock Gains 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:46AM CDT
Relypsa (RLYP) was a big mover last session, with shares rising over 13% on the day.

Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

Why Akorn (AKRX) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 7:34AM CDT
Akorn’s small price movement but large earnings estimate revisions make it an unappreciated stock that might have potential for gains

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FIU's PPRIM Device: A New Hope Against Preterm Births

Engineering a Leap in Prenatal Care Talk about flipping the script on prenatal diagnostics. A team from Florida International University (FIU) thinks they've got just the thing to spot early risks of preterm births with a device called PPRIM. It's the brainchild of some sharp minds, including FIU doctoral students Jenny Pei and Amanda Sanchez, and it's come out of FIU's...

Lower Salford Township Upgrades AED Access with Avive

Community Safety Takes Center Stage When it comes to community safety, the urgency can't be overstated, especially in a place like Lower Salford Township, Pennsylvania. This small township with around 16,000 residents has managed to pull off quite the feat in enhancing its emergency response capabilities by deploying 16 Avive Connect AED® devices throughout its police...

Protalix Posts Strong Gains, Eyes Future Milestones

Big Numbers and Bigger Ambitions Protalix BioTherapeutics has come out strong in their third quarter of 2026, showcasing some staggering numbers and laying out ambitious plans for the future. They've managed to pump their revenues up to a cool $75.6 million year-to-date, a leap from $43.6 million in the same period last year. You don't need a crystal ball to see them...

Cell Counting Market Growth: USD 17.71 Billion by 2031

The Cell Counting Surge: Money Talks in Science You can't deny it when the numbers speak—a jump from USD 12.39 billion to USD 17.71 billion by 2031 in the cell counting market means something ain't business as usual. That's a robust 7.40% CAGR folks; it's a field being bombarded with innovation. The spark? Automated and advanced cell analysis technology taking the...

Samsung Display's Cybersecurity Milestone in Auto Sector

Who would've thought we'd be tossing around terms like 'ISO certification' and 'cybersecurity' in the auto sector? Well, welcome to your new reality in 2026, where safeguarding our data is as critical as keeping engines running smoothly. Samsung Display just snagged an ISO/SAE 21434 certification along with an ENX Vehicle Cyber Security label. That's no small...

McEwen Faces Investigation Amid Declining Production

MUX Investors on Alert as Legal Stakes Rise The gold mining world isn't exactly flooded with excitement these days, and McEwen Inc.'s (NYSE: MUX) latest dealings ain't doing much to brighten up the scenery. When their third-quarter gold output took a nosedive—a 23% drop to be exact—it caught more eyes than a bull market will. Production Guidance in Question Now,...

Abbisko's PIMJETMI® Gains FDA Nod, Boosting TGCT Treatment

PIMJETMI® Scores FDA Approval, Expanding Global Reach Well, here's something to chew on over your morning coffee—PIMJETMI® (pimicotinib) just snagged the U.S. FDA's blessing to treat tenosynovial giant cell tumor (TGCT), making it another notch on Abbisko Therapeutics' belt. This approval is a strategic home run for Abbisko and their pals at Merck KGaA, Darmstadt,...

Munters Updates Financial Targets Amid Growth Plans

Munters' Bold New Targets and Strategic Moves Ever feel like you're on a constant treadmill chasing numbers? Munters Group knows the feeling. Over in Stockholm, they've just laid out fresh strategies at their Capital Markets Day—not just any pie-in-the-sky type goals, but heavy hitters that are setting the tone for their future. CEO Stefan Aspman is all geared up,...

Envista's $430M Senior Notes: A Market Move Decoded

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...

BD Sets Stage for Investor Day in December 2026

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...